» Therapeutic Expertise
 
  Research & Development:  
 

Innovation & Continuous Improvement in Process & Product innovation has been the key driver to our global success and has immensely shaped our competitive edge on the global platform.

Trigenesis Lifesciences has always been in the frontiers in developing unique formulations that makes a real difference in the quality of life of the people around the globe.  Every business idea ia reverse engineered to arrive at logically proven research capability. Stringent documentation  is preserved at every stage of R & D Activities to lay foundation for continuous improvement.

Transcending every hope into virtual reality, Trigenesis Lifesciences has developed many significant & noteworthy Capabilities in its thrust areas such as

  • Formulation development ,
  • Protein Purification ,
  • Analytical development &
  • Formulation development.

At Trigenesis Lifesciences Scientific Research through reverse engineering  is a tradition arising out of the global  mapping of its strategic planning process.

All R&D activities are adequately documented to ensure products tracebility & lay foundation for continuous research improvement.

These  strong  and gutsy R&D centres form  the DNA of our Company shaping our growth .
Our research capabilities include the following :

  • Product development parenterals
  • Sustained release injectable preparation (Microspheres)
  • Microdosage Tablets
  • Modified release Tablets & Capsules, pellets & Granules.
  • Sterile suspension / Oil based INJECTABLES
  • Stem Cell Line Research
  • Lyophilised formulation
  • Microemulsion solutions / Ointment & Creams


 



 
 
» Latest News
 


Launching new SBU’s in the Export Market.
Oxymony …..Life’s treasured..! Aiming as a “One stop pharma shop for the global village”, the SBU caters to the defined needs of the pharmaceutical market.by supplying Pharmaceutical commodities, Surgicals, Diagnostics, API’s, Food Supplements & Latex.
Expanding horizons with the Domestic division,Trigenesis is all set to enter the Indian Market with Biologicals i.e., TG-Glob (Intravenous immunoglobulin 2.5 mg, 5 mg) Biosimiliars TG-RHUFIL (GCSF 300 mcg) & Hormonals (Gonadotropins) by 2010.

 
   
  Powered By: MalnadTechnologies.Pvt.Ltd  
a